Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Nicholas Persich

Gastroenterology Metairie, LA Medical Doctor

NPI 1235245705 CMS profile 1024889

4228 Houma Blvd, Suite 120, Metairie, LA 70006

Open in the dashboard

General payments

$14,558

265 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Nicholas Persich of Metairie, LA is reported in the CMS Open Payments database as having received $14,558 across 265 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $23 1
2022 General $3,613 57
2021 General $6,207 77
2020 General $3,599 47
2019 General $1,115 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicholas Persich
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Nicholas Persich were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Nicholas Persich Gastroenterology median Middle half National median
2019 $1,115 $417 $126–$1,100 $163
2020 $3,599 $224 $74–$624 $114
2021 $6,207 $352 $106–$1,054 $132
2022 $3,613 $448 $129–$1,270 $149
2023 $0 $533 $150–$1,390 $160
2024 $23 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. RedHill Biopharma Inc. $11,232 16 payments
  2. AbbVie, Inc. $844 54 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $724 61 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $405 32 payments
  5. Janssen Biotech, Inc. $364 32 payments
  6. Gilead Sciences, Inc. $236 19 payments
  7. Pfizer Inc. $176 11 payments
  8. Allergan Inc. $173 13 payments
  9. Romark Laboratories, LC $91 5 payments
  10. Celgene Corporation $76 5 payments
  11. Other $237 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,770 7 payments
  2. Food and Beverage $3,616 253 payments
  3. Travel and Lodging $140 3 payments
  4. Education $32 2 payments
Products named General payments · program years 2019–2024
  1. Talicia $11,232 16 payments
  2. HUMIRA $690 43 payments
  3. XIFAXAN $488 38 payments
  4. STELARA $364 32 payments
  5. ENTYVIO $279 22 payments
  6. LINZESS $276 20 payments
  7. XELJANZ $176 11 payments
  8. TRULANCE Gastroenterology $167 18 payments
  9. TRULANCE Gastroenterology $100 8 payments
  10. ALINIA $91 5 payments
  11. Other $1,017 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

265 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record